4A1O
Crystal structure of Mycobacterium tuberculosis PurH complexed with AICAR and a novel nucleotide CFAIR, at 2.48 A resolution.
4A1O の概要
| エントリーDOI | 10.2210/pdb4a1o/pdb |
| 関連するPDBエントリー | 3ZZM |
| 分子名称 | BIFUNCTIONAL PURINE BIOSYNTHESIS PROTEIN PURH, POTASSIUM ION, AMINOIMIDAZOLE 4-CARBOXAMIDE RIBONUCLEOTIDE, ... (6 entities in total) |
| 機能のキーワード | transferase-hydrolase |
| 由来する生物種 | MYCOBACTERIUM TUBERCULOSIS |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 111576.64 |
| 構造登録者 | Le Nours, J.,Bulloch, E.M.M.,Zhang, Z.,Greenwood, D.R.,Middleditch, M.J.,Dickson, J.M.J.,Baker, E.N. (登録日: 2011-09-17, 公開日: 2011-09-28, 最終更新日: 2023-12-20) |
| 主引用文献 | Le Nours, J.,Bulloch, E.M.M.,Zhang, Z.,Greenwood, D.R.,Middleditch, M.J.,Dickson, J.M.J.,Baker, E.N. Structural Analyses of a Purine Biosynthetic Enzyme from Mycobacterium Tuberculosis Reveal a Novel Bound Nucleotide. J.Biol.Chem., 286:40706-, 2011 Cited by PubMed Abstract: Enzymes of the de novo purine biosynthetic pathway have been identified as essential for the growth and survival of Mycobacterium tuberculosis and thus have potential for the development of anti-tuberculosis drugs. The final two steps of this pathway are carried out by the bifunctional enzyme 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC), also known as PurH. This enzyme has already been the target of anti-cancer drug development. We have determined the crystal structures of the M. tuberculosis ATIC (Rv0957) both with and without the substrate 5-aminoimidazole-4-carboxamide ribonucleotide, at resolutions of 2.5 and 2.2 Å, respectively. As for other ATIC enzymes, the protein is folded into two domains, the N-terminal domain (residues 1-212) containing the cyclohydrolase active site and the C-terminal domain (residues 222-523) containing the formyltransferase active site. An adventitiously bound nucleotide was found in the cyclohydrolase active site in both structures and was identified by NMR and mass spectral analysis as a novel 5-formyl derivative of an earlier intermediate in the biosynthetic pathway 4-carboxy-5-aminoimidazole ribonucleotide. This result and other studies suggest that this novel nucleotide is a cyclohydrolase inhibitor. The dimer formed by M. tuberculosis ATIC is different from those seen for human and avian ATICs, but it has a similar ∼50-Å separation of the two active sites of the bifunctional enzyme. Evidence in M. tuberculosis ATIC for reactivity of half-the-sites in the cyclohydrolase domains can be attributed to ligand-induced movements that propagate across the dimer interface and may be a common feature of ATIC enzymes. PubMed: 21956117DOI: 10.1074/JBC.M111.291138 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.48 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






